Slaven Pikija

Near-infrared spectroscopy during mechanical Thrombectomy. I am trying to classify relationships between hemispheres (affected vs. unaffected). Did anybody have experience with it? #stroke #thrombectomy #spectroscopy #cerebral

Figure 2. Distribution of Modified Rankin Scale Scores at 90 Days

In patients with salvageable brain tissue identified by perfusion imaging who did not initially receive thrombectomy, alteplase given 4.5 to 24 hours after acute ischemic #stroke onset may improve functional outcomes.

ja.ma/4oOAoWx #MedSky #NeuroSky

Excellent case!

Also die "beste" Verschmutzung der Welt auch... :(

The treatment works, but kids can’t get it Terry Pirovolakis, a former IT professional from Canada, moved mountains and raised a fortune to shepherd a gene therapy for his son’s rare disorder through development. Now he is the go-to contact for other families facing the same dilemma: science has discovered the therapies and delivery technologies to treat their children, but it’s not profitable for drug companies to make them. Pirovolakis eventually founded his own company, Elpida Therapeutics, to bring such treatments to approval — but it relies on a patchwork of fundraising, tenuous grants and an obscure US government voucher program. Meanwhile, children’s health is slipping away. “I think what he’s doing is just extraordinary,” said Frédéric Revah, CEO of the French gene-therapy nonprofit Généthon. “But the whole field cannot depend on guys like Terry.” STAT | 18 min read (paywall)

I was absolutely bowled over by this feature in @statnews.bsky.social recommended by my colleague Sara Reardon in 'Nature Briefing: Translational Research' us17.campaign-archive.com?u=2c6057c528...

Neuroinflammation in Alzheimer disease - Nature Reviews Immunology This Review provides an in-depth examination of how inflammation contributes to neurodegeneration in Alzheimer disease. The authors explore the impact of extrinsic factors, such as brain trauma, diet ...

it's big, and it's a review of 601 papers on the topic - but here's an update on Neuroinflammation in Alzheimer's Disease
www.nature.com/articles/s41...

led by Michael Heneka, published in @natrevimmunol.bsky.social today

(MANY more authors listed and linked below)

Cartoon which mimics The Great Wave off Kanagawa, but the wave is made of research papers and the boat is full of lab coated researchers

I'm sure this Science story on how systematic reviews are threatened by paper mills is good, but the illustration by Sara Gironi Carnevale is great

saragironicarnevale.com

Story: https://www.science.org/content/article/systematic-reviews-aim-extract-broad-conclusions-many-studies-are-peril

Best animation ever!

Useful read on statistics and o values!🧪🧠

In my opinion (as a user, not an statistics expert), the p value is a tool to agree that something may be going on. Without context or further confirmation by independent experimental approaches, it means nothing.
It is not sacred evidence of an effect.

Cortical ribboning of the Northern Lights #neurosky #epilepsy

Agree. Instead of reinventing the wheel we can still use plain old CT+CTP to detect acute and relevant lesions in patients treated with ATT and presenting with emergent symptoms. Still waiting that someone prove otherwise. Cheers

Common gene variant APOE4 offers clues for new Alzheimer’s drug A study of the impact of a genetic variant that can increase Alzheimer’s risk, APOE4, could clear the path for creating an effective drug.

Stanford Medicine neurologist Michael Greicius, MD,
spearheaded a recent groundbreaking genetics study focusing on Alzheimer's disease. This study examines the impact of gene variants, particularly APOE4, on Alzheimer's risk and treatment responses.. stanmed.stanford.edu/alzheimers-v...

November is Epilepsy Awareness Month, and we recognize the millions of people worldwide who live with this brain disorder. We stand with them and their families, caregivers, and loved ones in the fight to continue advancements and find a cure. #EpilepsyAwareness

I agree. The neurology focused feed would be nice too.

Pylustrator offers an interactive interface to find the best way to present your data in a figure for publication. Added formatting and styling can be saved by automatically generated code. https://pylustrator.readthedocs.io/en/latest/ #python

What a find (via @floragraham.bsky.social)!

The Journal of Universal Rejection, www.universalrejection.org, to which “all submissions, regardless of quality, will be rejected”. Can't wait to go to their conference! Oops! That has been canceled! 😆
#AcademicSky 🧪 ⚒️ #scipol

Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies - Acta Neuropathologica Tau PET has attracted increasing interest as an imaging biomarker for 4-repeat (4R)-tauopathy progressive supranuclear palsy (PSP). However, the translation of in vitro 4R-tau binding to in vivo tau P...

Massive paper alert: We performed extensive profiling of PI-2620 for 4R tauopathies. PI-2620 tau PET signals in PSP stem from neuronal and oligodendroglial tau, not astrocytes. Signals correlate with fibrillary tau, autoradiography, and autopsy data in PSP
doi.org/10.1007/s004...

Looking forward to! Best

I agree about binary outcomes. However, it is more often the case to encounter one-way reasoning—comparing two features that are, by their nature, interval variables and arbitrarily choosing one to binarize or categorize. I have done this myself as well. Perhaps it is time to reconsider.

Looking up all ~550 cases that we saw over ~10 years in our memory clinics, with both CSF and Aβ-PET obtained in clinical routine was a huge team effort, co-coordinated by
Matthias Brendel, Günter Höglinger, colleagues from the University of Vienna and many others! Thanks to all!

Kudos to the authors on an excellent paper! It is a remarkable undertaking, though at times dense to read. As the authors note, PET-CT was considered the ground truth, albeit with several caveats—it provided a binary outcome without quantification. #Alzheimers #Biomarkers

New paper alert: A two-cutoff CSF Aβ42/40 approach improves Aβ detection in real world clinical settings. CSF Aβ42/40≥7.1 rules out amyloid, while ratios~5.5–7.1 benefit from Aβ PET. Key for Lecanemab stratification. #Alzheimers #Biomarkers
📄read more: doi.org/10.1002/dad2...

Hello science world 👋, the Dormann Lab now also migrated to Bluesky...

Follow us if you are interested in neurodegeneration or condensation research!

Kein Wunder. Der letzte Weltkrieg hat den (in)direkten Warenhandel zwischen den Kriegsparteien eben nicht vollständig stillgelegt – oder liege ich da falsch?

An interesting clinical case seen yesterday: a man in his early 20-ies experienced sudden room tilt of 90-120 degrees alternating for 30 minutes long with associated autonomic symptoms. Presenting after 10 days still having occasional dizziness but without residual deficits. What is your diagnosis?

What is the best use-case for modules in Retool? #retool

Das mit DC habe gar nicht mitbekommen... Worum geht es überhaupt?

All the best! Can't wait to see results.

Excellent news! Can't wait to offer this option at my centre.

It is time to start a conversation about alternative imaging strategies for patients undergoing anti-amyloid therapy. Is MRI always feasible? Could CT multimodal imaging serve as a viable alternative? The tide is rising, and we must be prepared.